RecruitingNot ApplicableNCT02361320

Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer

Imaging Biomarkers in Pancreatic and Hepatobiliary Cancers

Sponsor

M.D. Anderson Cancer Center

Enrollment

259 participants

Start Date

Mar 9, 2015

Study Type

INTERVENTIONAL

Conditions

Pancreatic Cancer

Summary

This trial studies how well computed tomography works in diagnosing patients with pancreatic or hepatobiliary cancer. Computed tomography may help researchers predict how patients with pancreatic or hepatobiliary cancer may respond to chemotherapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is evaluating whether CT perfusion scans — special CT scans that measure blood flow through a tumor — can predict how well pancreatic or liver/bile duct cancers respond to treatment. **You may be eligible if...** - You have been confirmed by biopsy to have pancreatic cancer or cancer of the liver or bile ducts (hepatobiliary cancer) - Your cancer is locally advanced (has not spread to distant organs but cannot easily be removed with surgery), or is borderline resectable (may become operable after treatment) - You are scheduled for chemotherapy or radiation treatment - You are 18 or older and able to give consent **You may NOT be eligible if...** - Your cancer has already spread to distant organs - You are unable to receive CT contrast dye (for example, due to kidney problems or allergy) - You are pregnant - You are unable to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREComputed Tomography (CT)

Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.

BEHAVIORALQuestionnaire

Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.